Spyre Therapeutics (SYRE) director receives option grant for 8,026 shares

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. director Mark C. McKenna received a grant of stock options covering 8,026 shares of common stock. These options carry an exercise price of $72.51 per share and expire on May 27, 2036.

The options will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of Spyre Therapeutics’ 2027 annual meeting of stockholders, provided McKenna continues serving the company through the vesting date. After this grant, he holds 8,026 derivative securities directly from this award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider McKenna Mark C.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,026	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 8,026 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 8,026 shares Exercise price: $72.51 per share Expiration date: May 27, 2036 +1 more

4 metrics

Option shares granted 8,026 shares Stock option grant to director on May 27, 2026

Exercise price $72.51 per share Stock option strike price

Expiration date May 27, 2036 Option term end date

Vesting date trigger Earlier of May 27, 2027 or 2027 annual meeting Vesting condition, subject to continuous service

Key Terms

Stock Option (Right to Buy), exercise price, vest and become fully exercisable, continuous service

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price": "72.5100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become fully exercisable financial

"which will vest and become fully exercisable upon the earlier of May 27, 2027"

continuous service financial

"subject to the Reporting Person's continuous service to the Issuer"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKenna Mark C.

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23

SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$72.51	05/27/2026		A		8,026		(1)	05/27/2036	Common Stock	8,026	$0	8,026	D

Explanation of Responses:

1. This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Spyre Therapeutics (SYRE) director Mark C. McKenna report on this Form 4?

Mark C. McKenna reported receiving a stock option grant for 8,026 shares of Spyre Therapeutics common stock. The award is a compensation-related acquisition, not an open-market purchase or sale, and is structured as a right to buy shares in the future.

How many Spyre Therapeutics (SYRE) shares are covered by McKenna’s new stock option?

The stock option covers 8,026 shares of Spyre Therapeutics common stock. This number reflects the underlying shares tied to the option grant and equals the total derivative securities McKenna holds following this reported transaction.

What is the exercise price and expiration date of McKenna’s Spyre Therapeutics (SYRE) option grant?

The option has an exercise price of $72.51 per share and expires on May 27, 2036. This means McKenna can purchase shares at $72.51 up until that expiration date once the option is vested and exercisable.

When do Mark C. McKenna’s Spyre Therapeutics (SYRE) options vest?

The options vest and become fully exercisable on the earlier of May 27, 2027 or Spyre Therapeutics’ 2027 annual meeting of stockholders. Vesting is conditioned on McKenna’s continuous service to the company through the applicable vesting date.

Is McKenna’s Spyre Therapeutics (SYRE) Form 4 transaction a market purchase or sale?

No, this Form 4 reflects a compensation-related stock option grant, coded as an acquisition (A). It is not an open-market buy or sell; instead, it grants McKenna the right to buy shares in the future at a fixed exercise price.